Dimensional International High Profitability ETF
DIHP - ETF AI Analysis
Top Page
Dimensional International High Profitability ETF (DIHP)
DIHP, the Dimensional International High Profitability ETF, has a solid overall rating driven mainly by strong, profitable companies like ASML, Novartis, and AstraZeneca, which show healthy financials, positive business outlooks, and supportive technical trends. The fund’s score is held back somewhat by holdings where valuations look stretched or short-term momentum is weaker, such as Roche and BHP, and by several stocks with signs of potential overvaluation. A key risk factor is that many top holdings share similar valuation concerns, meaning the ETF could be more sensitive if market sentiment turns against higher-priced international stocks.
DIHP vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.60B
- Region
- Developed Markets
- Expense Ratio
- 0.27%
- Beta
- 0.69
- Issuer
- Dimensional
- Inception Date
- Mar 23, 2022
- Dividend Yield
- 2.02%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
DIHP Summary
Dimensional International High Profitability ETF (DIHP) is an international stock fund that focuses on large, highly profitable companies outside the U.S., rather than tracking a specific index. It spreads your money across many countries and sectors, aiming for steady growth from strong, established businesses. Well-known holdings include Nestlé and Sony, along with major healthcare and technology firms. Someone might invest in DIHP to diversify beyond the U.S. and tap into global companies with solid earnings. A key risk is that international stock prices can go up and down with global markets and currency swings.
How much will it cost me?
This ETF has an expense ratio of 0.27%, which means you’ll pay about $2.70 per year for every $1,000 invested. That’s slightly higher than the average low-cost index ETF because it’s actively managed, using Dimensional’s strategy to focus on high-profitability international companies.
What would affect this ETF?
Future returns for DIHP will likely be helped if developed markets outside the U.S. grow steadily, global demand for technology, health care, and consumer staples stays strong, and profitable giants like ASML, Roche, and Nestlé continue to perform well. On the other hand, slower economic growth abroad, rising interest rates, currency swings, or tighter regulations on big drug, tech, or resource companies such as BHP could weigh on the ETF’s performance.
DIHP Top 10 Holdings
DIHP is leaning heavily on a mix of global health care and chip-related powerhouses, with Roche and Novartis providing steady, rising support while AstraZeneca has been more of a laggard lately. On the tech side, ASML and Tokyo Electron are key drivers, though their recent pullbacks show that semiconductor exposure can cut both ways. Japanese names like Advantest and Recruit have been standout risers, giving the fund a strong lift. Overall, it’s a developed-markets ex-U.S. story, anchored in profitable European and Japanese leaders rather than U.S. Big Tech.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 ASML | ASML Holding | 3.27% | $215.05M | $576.89B | 50.08% | 81Outperform |
 CH:NESN | Nestlé SA | 2.11% | $138.61M | CHF 222.27B | 5.72% | 71Outperform |
 JP:6758 | Sony | 1.96% | $128.63M | JPY 25.11T | -7.08% | 73Outperform |
 AU:BHP | BHP Group Ltd | 1.58% | $103.55M | AUD 304.35B | 41.13% | 68Neutral |
 NVS | Novartis | 1.46% | $95.99M | $295.79B | 22.85% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 JP:6098 | Recruit Holdings Co | 1.38% | $90.38M | JPY 24.90T | 113.78% | 67Neutral |
 JP:6857 | Advantest | 1.17% | $76.61M | JPY 20.71T | 58.19% | 75Outperform |
 JP:8035 | Tokyo Electron | 1.20% | $78.50M | JPY 20.95T | 35.60% | 73Outperform |
DIHP Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DIHP, the sentiment is Positive. The current price of 34.22 is above the 20-day moving average (MA) of 34.09, above the 50-day MA of 34.14, and above the 200-day MA of 33.73, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 55.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DIHP.
DIHP Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| DIHP | $34.22 | $36.00(5.22% Upside) | $6.60B | 0.27% | 67Neutral |
 DFIS | $35.87 | ― | $5.80B | 0.39% | 58Neutral |
 CGIE | $36.63 | $44.44(21.32% Upside) | $2.46B | 0.54% | 66Neutral |
 AVIV | $80.09 | $93.96(17.32% Upside) | $2.10B | 0.25% | 68Neutral |
 TOUS | $38.49 | $47.21(22.64% Upside) | $1.73B | 0.50% | 65Neutral |
 SEIE | $35.87 | $40.73(13.55% Upside) | $1.33B | 0.50% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DIHP | Dimensional International High Profitability ETF | 34.22 | 3.73 | 12.22% | |
| DFIS | Dimensional International Small Cap ETF | 35.87 | 5.02 | 16.27% | |
| CGIE | Capital Group International Equity ETF | 36.63 | 2.53 | 7.41% | |
| AVIV | Avantis International Large Cap Value ETF | 80.09 | 12.78 | 18.98% | |
| TOUS | T. Rowe Price International Equity ETF | 38.49 | 4.93 | 14.68% | |
| SEIE | SEI Select International Equity ETF | 35.87 | 5.06 | 16.43% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.